Production (Stage)
Bright Minds Biosciences Inc.
DRUG
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -5,907.34% | 106.44% | -465.29% | 135.31% | 65.60% |
| Total Depreciation and Amortization | 1.95% | 10.79% | 5.30% | -1.49% | 0.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 143.22% | -911.38% | 2.74% | -27.61% | -11.79% |
| Change in Net Operating Assets | -14.05% | -223.65% | 161.11% | 68.51% | -183.53% |
| Cash from Operations | -58.29% | -214.37% | -293.50% | 129.39% | 1.17% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3.36% | 0.42% | -8.64% | 0.00% | 0.00% |
| Issuance of Common Stock | -99.50% | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | 835,100.00% | -- | -- | -- |
| Cash from Financing | -99.58% | 214,993.64% | -8.13% | 1.84% | -102.53% |
| Foreign Exchange rate Adjustments | -101.00% | 9,445.08% | -57.79% | 1,906.25% | 94.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -104.14% | 10,913.32% | -282.96% | 130.63% | -6,250.00% |